A novel oral GLP-1 medication known as aleniglipron has demonstrated the ability to aid individuals dealing with obesity or excess weight in shedding approximately 12% of their body mass over a span of 36 weeks, as revealed by recent research from Northwestern University published in Nature Medicine. Unlike injectable options such as Wegovy and Ozempic, aleniglipron is a small-molecule tablet that can be consumed once daily, irrespective of meals. The study monitored 230 participants with overweight or obesity across 38 medical facilities in the U.S., administering three increasing doses throughout the trial duration. The medication functions by enhancing insulin release, curbing appetite, and promoting a sense of fullness. Reported side effects were primarily mild to moderate gastrointestinal discomfort that subsided over time, with no new safety issues or liver injury cases noted by researchers. While aleniglipron has yet to receive FDA approval, its developer, Structure Therapeutics, is advancing towards Phase 3 trials. Experts suggest that the pill form could render effective obesity management more attainable compared to daily injections.
Disclosure:
This video contains stock footage and content created or enhanced using AI-assisted tools.
ai-generated
